Velaglucerase alfa
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.[2] It is manufactured by Shire plc.
| Clinical data | |
|---|---|
| Trade names | Vpriv |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Elimination half-life | Plasma: 5–12 minutes (absorbed by macrophages) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2532H3850N672O711S16 |
| Molar mass | 55593.61 g·mol−1 |
  (what is this?) (verify) | |
The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.[3]
Velaglucerase alfa was approved for medical use in the United States in February 2010,[4][5] and in the European Union in August 2010.[3]
